Mental bulimia , paroxetine treatment and phenotype monitoring
of CYP2D6 activity

D 2007

Mental bulimia , paroxetine treatment and phenotype monitoring of CYP2D6 activity

PALČÍKOVÁ, Ivana, Alexandra ŽOURKOVÁ, Daria VALENTOVÁ a Eva HADAŠOVÁ

Základní údaje

Originální název

Mental bulimia , paroxetine treatment and phenotype monitoring of CYP2D6 activity

Název česky

Sledování fenotypových změn CYP2D6 při léčbě bulimie paroxetinem

Autoři

PALČÍKOVÁ, Ivana, Alexandra ŽOURKOVÁ, Daria VALENTOVÁ a Eva HADAŠOVÁ

Vydání

Brno, Addiction and Eating Disorders, Neurobiology nad Comorbidities, Workshop, od s. 59-60, 2 s. 2007

Nakladatel

Masaryk University Conference Centre, Czech Republic, Brno

Další údaje

Jazyk

angličtina

Typ výsledku

Stať ve sborníku

Obor

30000 3. Medical and Health Sciences

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Organizační jednotka

Lékařská fakulta

ISBN

978-80-87041-18-5

Klíčová slova anglicky

bulimia; CYP2D6; paroxetine

Štítky

bulimia, CYP2D6, paroxetine

Změněno: 20. 5. 2007 15:50, MUDr. Ivana Palčíková

Anotace

ORIG CZ

V originále

P450 enzymes are oxidase systems. These enzymes oxidize endogenous and exogenous compounds and usually render them less active, preparing them for elimination from the body. More than 40 individual P450 enzymes have been identified. 2D6 play important role in drug metabolism. SSRI (serotonin reuptake inhibitors) therapy is used in bulimia. There are SSRI, especially paroxetine, with a SSRI-inhibiting effect. This fact may lead to a change of phenotype. Phenotyping enables to identify the current activity of the enzyme. The study included patients diagnosed with bulimia. The goal of the study was to evaluate the efficacy of paroxetine treatment in female patients with mental bulimia (MB) while monitoring CYP2D6 activity. Treatment was evaluated on EAT, HAMA, CGI and UKU scales. CYP2D6 activity phenotyping was performed using the dextromethorphan test. The expectation of a significant improvement in poor metabolizers and consequently slower paroxetine degradation was confirmed on the scale for eating behaviour.

Česky

Léčba pacientek s mentální bulimií byla hodnocena prostřednictvím škál EAT, HAMA, CGI a UKU. Fenotypizace probíhala prostřednictvím dextrometorfanového testu. Očekávané zlepšení u bulimických pacientek s pomalou metabolizací se potvrdilo na škále EAT.

Návaznosti

MSM0021622404, záměr

Název: Vnitřní organizace a neurobiologické mechanismy funkčních systémů CNS

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Vnitřní organizace a neurobiologické mechanismy funkčních systémů CNS

Citovat

PALČÍKOVÁ, Ivana, Alexandra ŽOURKOVÁ, Daria VALENTOVÁ a Eva HADAŠOVÁ. Mental bulimia , paroxetine treatment and phenotype monitoring of CYP2D6 activity. In Addiction and Eating Disorders, Neurobiology nad Comorbidities, Workshop. Brno: Masaryk University Conference Centre, Czech Republic, Brno, 2007, s. 59-60. ISBN 978-80-87041-18-5.

@inproceedings{718302,
   author = {Palčíková, Ivana and Žourková, Alexandra and Valentová, Daria and Hadašová, Eva},
   address = {Brno},
   booktitle = {Addiction and Eating Disorders, Neurobiology nad Comorbidities, Workshop},
   keywords = {bulimia; CYP2D6; paroxetine},
   language = {eng},
   location = {Brno},
   isbn = {978-80-87041-18-5},
   pages = {59-60},
   publisher = {Masaryk University Conference Centre, Czech Republic, Brno},
   title = {Mental bulimia , paroxetine treatment and phenotype monitoring of CYP2D6 activity},
   year = {2007}
}

TY  - JOUR
ID  - 718302
AU  - Palčíková, Ivana - Žourková, Alexandra - Valentová, Daria - Hadašová, Eva
PY  - 2007
TI  - Mental bulimia , paroxetine treatment and phenotype monitoring of CYP2D6 activity
PB  - Masaryk University Conference Centre, Czech Republic, Brno
CY  - Brno
SN  - 9788087041185
KW  - bulimia
KW  - CYP2D6
KW  - paroxetine
N2  - P450 enzymes are oxidase systems. These enzymes oxidize endogenous and exogenous compounds and usually render them less active, preparing them for elimination from the body. More than 40 individual P450 enzymes have been identified. 2D6 play important role in drug metabolism. SSRI (serotonin reuptake inhibitors) therapy is used in bulimia. There are SSRI, especially paroxetine, with a SSRI-inhibiting effect. This fact may lead to a change of phenotype. Phenotyping enables to identify the current activity of the enzyme. The study included patients diagnosed with bulimia. The goal of the study was to evaluate the efficacy of paroxetine treatment in female patients with mental bulimia (MB) while monitoring CYP2D6 activity. Treatment was evaluated on EAT, HAMA, CGI and UKU scales. CYP2D6 activity phenotyping was performed using the dextromethorphan test. The expectation of a significant improvement in poor metabolizers and consequently slower paroxetine degradation was confirmed on the scale for eating behaviour.
ER  -

PALČÍKOVÁ, Ivana, Alexandra ŽOURKOVÁ, Daria VALENTOVÁ a Eva HADAŠOVÁ. Mental bulimia , paroxetine treatment and phenotype monitoring of CYP2D6 activity. In \textit{Addiction and Eating Disorders, Neurobiology nad Comorbidities, Workshop}. Brno: Masaryk University Conference Centre, Czech Republic, Brno, 2007, s.~59-60. ISBN~978-80-87041-18-5.

Podrobný výpis o publikaci